Oppenheimer Reaffirms Its Outperform Rating on argenx SE (ARGX)
On September 18, following the company’s ARGX-119 R&D Spotlight event, Oppenheimer reaffirmed its Outperform rating on argenx SE (NASDAQ:ARGX), citing encouraging clinical proof-of-concept evidence ...